勘误：日本视网膜分支静脉阻塞继发黄斑水肿患者从雷珠单抗转换为阿柏西普治疗后注射间隔时间的延长 [勘误]
Erratum: Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion [Corrigendum].
出版信息
Clin Ophthalmol. 2017 Apr 5;11:619. doi: 10.2147/OPTH.S136670. eCollection 2017.
Abstract
[This corrects the article on p. 403 in vol. 11, PMID: 28260852.].
摘要
[这更正了第11卷第403页上的文章，PMID: 28260852。]
相似文献
1
Erratum: Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion [Corrigendum].勘误：日本视网膜分支静脉阻塞继发黄斑水肿患者从雷珠单抗转换为阿柏西普治疗后注射间隔时间的延长 [勘误]
Clin Ophthalmol. 2017 Apr 5;11:619. doi: 10.2147/OPTH.S136670. eCollection 2017.
2
Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion.在日本视网膜分支静脉阻塞继发黄斑水肿患者中，从雷珠单抗转换为阿柏西普治疗后延长注射间隔时间。
Clin Ophthalmol. 2017 Feb 22;11:403-408. doi: 10.2147/OPTH.S128651. eCollection 2017.
3
Effect of aflibercept on persistent macular edema secondary to central retinal vein occlusion.阿柏西普对视网膜中央静脉阻塞继发的持续性黄斑水肿的影响。
J Fr Ophtalmol. 2018 Nov;41(9):809-813. doi: 10.1016/j.jfo.2018.01.024. Epub 2018 Oct 22.
4
Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.在视网膜中央静脉阻塞中从雷珠单抗和/或贝伐单抗转换为阿柏西普治疗后的临床结局
Ophthalmic Res. 2015;54(3):150-6. doi: 10.1159/000439223. Epub 2015 Sep 29.
5
Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.阿柏西普和雷珠单抗“治疗并监测”方案用于非缺血性视网膜分支静脉阻塞继发黄斑水肿的疗效
Int Ophthalmol. 2019 Jan;39(1):145-153. doi: 10.1007/s10792-017-0798-6. Epub 2017 Dec 22.
6
Aflibercept in branch retinal vein occlusion as second line therapy: clinical outcome 12 months after changing treatment from bevacizumab/ranibizumab-a pilot study.阿柏西普用于视网膜分支静脉阻塞的二线治疗：从贝伐单抗/雷珠单抗换药12个月后的临床结果——一项前瞻性研究
Int J Retina Vitreous. 2016 Aug 23;2:20. doi: 10.1186/s40942-016-0045-8. eCollection 2016.
7
The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion.在缺血性中央静脉阻塞继发黄斑水肿的难治性病例中，将雷珠单抗换用阿柏西普的效果。
Klin Monbl Augenheilkd. 2015 Apr;232(4):552-5. doi: 10.1055/s-0035-1545783. Epub 2015 Apr 22.
8
Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective.雷珠单抗与阿柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的成本效益：英国医疗保健视角
Adv Ther. 2016 Jan;33(1):116-28. doi: 10.1007/s12325-015-0279-0. Epub 2016 Jan 8.
9
Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab.雷珠单抗治疗无效的视网膜中央静脉阻塞继发黄斑水肿患者改用阿柏西普治疗的效果
Int Ophthalmol. 2018 Feb;38(1):207-213. doi: 10.1007/s10792-017-0512-8. Epub 2017 Apr 12.
10
Comparison of ranibizumab and subthreshold micropulse laser in treatment of macular edema secondary to branch retinal vein occlusion.雷珠单抗与阈下微脉冲激光治疗视网膜分支静脉阻塞继发黄斑水肿的比较。
Eur J Ophthalmol. 2018 Nov;28(6):690-696. doi: 10.1177/1120672117750056. Epub 2018 Apr 26.
Zotero 插件